Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.
Mol Metab. 2022 Jan;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 1.
Mol Metab. 2022.
PMID: 34863941
Free PMC article.